3,4-Difluoroamphetamine
3,4-Difluoroamphetamine (DFA) is a substituted amphetamine which has been sold as a designer drug. It has relatively weak activity as a serotonin releasing agent with only around 1/4 of the affinity for the serotonin transporter compared to MDA, but its activity at other targets has not been studied.[1][2]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H11F2N |
Molar mass | 171.191 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL (February 2004). "Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters". The Journal of Pharmacology and Experimental Therapeutics. 308 (2): 679–687. doi:10.1124/jpet.103.057836. PMID 14593087. S2CID 6439942.
- Walline CC, Nichols DE, Carroll FI, Barker EL (June 2008). "Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 791–800. doi:10.1124/jpet.108.136200. PMC 2637348. PMID 18354055.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.